RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
/ RIVERVEST NEWS
Wugen, Inc.
Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer – 2/26/2025
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments – 1/30/2025
Atalanta Therapeutics Closes Oversubscribed $97 Million Series B Financing to Advance Two RNAi Therapies for CNS Diseases to Clinical Trial – 1/28/2025
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta- 1/21/2025
Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Pivotal Trial Program – 1/14/2025
Novel Heart Failure Technology from Alleviant Medical Gains FDA Approval for New Pivotal Trial and Breakthrough Designation for Significant Patient Population – 1/7/2025
Subscribe to our newsletter